Literature DB >> 23925046

Activity of the clinical-stage CK2-specific inhibitor CX-4945 against chronic lymphocytic leukemia.

L R Martins1, P Lúcio2, A Melão1, I Antunes1, B A Cardoso1, R Stansfield3, M T S Bertilaccio4, P Ghia5, D Drygin3, M G Silva2, J T Barata1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23925046     DOI： 10.1038/leu.2013.232

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells.

Authors:  S Cuní; P Pérez-Aciego; G Pérez-Chacón; J A Vargas; A Sánchez; F M Martín-Saavedra; S Ballester; J García-Marco; J Jordá; A Durántez
Journal:  Leukemia       Date:  2004-08       Impact factor: 11.528

Review 2.  Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways.

Authors:  F Piazza; S Manni; M Ruzzene; L A Pinna; C Gurrieri; G Semenzato
Journal:  Leukemia       Date:  2012-01-13       Impact factor: 11.528

3.  Mechanisms of apoptosis-induction by rottlerin: therapeutic implications for B-CLL.

Authors:  I Ringshausen; M Oelsner; K Weick; C Bogner; C Peschel; T Decker
Journal:  Leukemia       Date:  2006-03       Impact factor: 11.528

Review 4.  Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy.

Authors:  S Faderl; A Ferrajoli; O Frankfurt; A Pettitt
Journal:  Leukemia       Date:  2008-11-06       Impact factor: 11.528

5.  Reconstitution of PTEN activity by CK2 inhibitors and interference with the PI3-K/Akt cascade counteract the antiapoptotic effect of human stromal cells in chronic lymphocytic leukemia.

Authors:  Medhat Shehata; Susanne Schnabl; Dita Demirtas; Martin Hilgarth; Rainer Hubmann; Elena Ponath; Sigrun Badrnya; Claudia Lehner; Andrea Hoelbl; Markus Duechler; Alexander Gaiger; Christoph Zielinski; Josef D Schwarzmeier; Ulrich Jaeger
Journal:  Blood       Date:  2010-06-24       Impact factor: 22.113

Review 6.  Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options.

Authors:  Apostolia-Maria Tsimberidou; Michael J Keating
Journal:  Leuk Lymphoma       Date:  2010-07

Review 7.  Update on therapy of chronic lymphocytic leukemia.

Authors:  John G Gribben; Susan O'Brien
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

8.  CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.

Authors:  Adam Siddiqui-Jain; Denis Drygin; Nicole Streiner; Peter Chua; Fabrice Pierre; Sean E O'Brien; Josh Bliesath; Mayuko Omori; Nanni Huser; Caroline Ho; Chris Proffitt; Michael K Schwaebe; David M Ryckman; William G Rice; Kenna Anderes
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

9.  Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia.

Authors:  Leila R Martins; Paulo Lúcio; Milene C Silva; Kenna L Anderes; Paula Gameiro; Maria G Silva; João T Barata
Journal:  Blood       Date:  2010-07-21       Impact factor: 22.113

10.  p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression.

Authors:  S el Rouby; A Thomas; D Costin; C R Rosenberg; M Potmesil; R Silber; E W Newcomb
Journal:  Blood       Date:  1993-12-01       Impact factor: 22.113
View more
  41 in total

1.  Casein Kinase 2: a novel player in glioblastoma therapy and cancer stem cells.

Authors:  Maya Agarwal; Ryan T Nitta; Gordon Li
Journal:  J Mol Genet Med       Date:  2013-12-09

2.  Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2.

Authors:  S Manni; D Toscani; E Mandato; A Brancalion; L Quotti Tubi; P Macaccaro; A Cabrelle; F Adami; R Zambello; C Gurrieri; G Semenzato; N Giuliani; F Piazza
Journal:  Leukemia       Date:  2014-06-04       Impact factor: 11.528

Review 3.  Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia.

Authors:  Chandrika Gowda; Mario Soliman; Malika Kapadia; Yali Ding; Kimberly Payne; Sinisa Dovat
Journal:  Adv Biol Regul       Date:  2017-06-13

4.  Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Ivo Veletic; Alessandra Ferrajoli; Jan Burger; Susan O'Brien; Prithviraj Bose; Philip Thompson; Nitin Jain; William Wierda; Michael J Keating; Zeev Estrov
Journal:  Mol Cancer Res       Date:  2017-01-27       Impact factor: 5.852

5.  CK2α' Drives Lung Cancer Metastasis by Targeting BRMS1 Nuclear Export and Degradation.

Authors:  Yuan Liu; Elianna B Amin; Marty W Mayo; Neel P Chudgar; Peter R Bucciarelli; Kyuichi Kadota; Prasad S Adusumilli; David R Jones
Journal:  Cancer Res       Date:  2016-03-15       Impact factor: 12.701

6.  Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia.

Authors:  A Lonetti; I L Antunes; F Chiarini; E Orsini; F Buontempo; F Ricci; P L Tazzari; P Pagliaro; F Melchionda; A Pession; A Bertaina; F Locatelli; J A McCubrey; J T Barata; A M Martelli
Journal:  Leukemia       Date:  2013-11-06       Impact factor: 11.528

7.  Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.

Authors:  F Buontempo; E Orsini; L R Martins; I Antunes; A Lonetti; F Chiarini; G Tabellini; C Evangelisti; C Evangelisti; F Melchionda; A Pession; A Bertaina; F Locatelli; J A McCubrey; A Cappellini; J T Barata; A M Martelli
Journal:  Leukemia       Date:  2013-11-20       Impact factor: 11.528

8.  Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.

Authors:  Chunhua Song; Chandrika Gowda; Xiaokang Pan; Yali Ding; Yongqing Tong; Bi-Hua Tan; Haijun Wang; Sunil Muthusami; Zheng Ge; Mansi Sachdev; Shantu G Amin; Dhimant Desai; Krishne Gowda; Raghavendra Gowda; Gavin P Robertson; Hilde Schjerven; Markus Muschen; Kimberly J Payne; Sinisa Dovat
Journal:  Blood       Date:  2015-07-28       Impact factor: 22.113

9.  CK2 regulates 5-HT4 receptor signaling and modulates depressive-like behavior.

Authors:  J Castello; B LeFrancois; M Flajolet; P Greengard; E Friedman; H Rebholz
Journal:  Mol Psychiatry       Date:  2017-11-21       Impact factor: 15.992

10.  Phosphoproteomics Identifies CK2 as a Negative Regulator of Beige Adipocyte Thermogenesis and Energy Expenditure.

Authors:  Kosaku Shinoda; Kana Ohyama; Yutaka Hasegawa; Hsin-Yi Chang; Mayu Ogura; Ayaka Sato; Haemin Hong; Takashi Hosono; Louis Z Sharp; David W Scheel; Mark Graham; Yasushi Ishihama; Shingo Kajimura
Journal:  Cell Metab       Date:  2015-11-08       Impact factor: 27.287
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.